Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin to Reduce Inflammation After Tuberculosis Treatment
NCT04147286Phase 3Recruiting
- Sponsor
- University of Cape Town
- Start
- Jul 2020
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atorvastatin in Tuberculosis (TB), sponsored by University of Cape Town. Primary endpoint: Total lung glycolysis at 12 weeks. Started Jul 2020; status: recruiting.
02
Drugs
atorvastatin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04147286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04147286.